Michael Spencer

Michael explores how generative AI can revolutionize drug discovery and clinical trials, breaking biotech's decades-long stagnation. Despite rapid technological progress, drug development has slowed, with costs skyrocketing and approvals dwindling - a phenomenon termed Eroom's Law. AI tools like AlphaFold can predict biomolecular structures, enabling optimal drug design rather than screening. AI can simulate molecular dynamics, enhance selectivity, and enable personalized medicine. Companies like Insilico Medicine are already accelerating drug discovery using AI. Beyond that, AI can optimize clinical trials through predictive modeling, seamless patient recruitment, adaptive designs, and real-time monitoring, reducing time and costs. By embracing AI, biotech can overcome its 'death spiral' and unlock a new era of rapid therapeutic innovation.